Le Lézard
Classified in: Health, Science and technology
Subject: AWD

Allucent Recognized with CRO Leadership Awards for Expertise and Compatibility


CARY, N.C., May 2, 2024 /PRNewswire/ -- Allucent, a global mid-sized clinical research organization (CRO), received two CRO Leadership Awards presented by Clinical Leader and Life Science Connect for the second consecutive year. Recipients of these awards are determined based on research conducted by Industry Standard Research (ISR) to identify CROs that meet or exceed their customers' expectations. This year, Allucent received awards in the Expertise and Compatibility categories across Small Pharma and Overall (Big and Small Pharma combined).

"We're honored to be recognized through the CRO Leadership Awards for the second consecutive year," said Mark A. Goldberg, M.D., chairman and chief executive officer of Allucent. "Exactly two years ago this month we launched under the Allucent brand with a laser focus on helping small and mid-sized biotech companies solve their toughest challenges by bringing unsurpassed value and a true partnership approach. These awards are a testament to our A-team's ability to deliver on that mission. We look forward to continuing to exceed expectations as we help sponsors navigate and accelerate their drug development journeys in the years ahead."

To determine the award winners, 42 contract research organizations were assessed on more than 20 performance metrics through ISR's annual CRO Quality Benchmarking survey. Survey respondents were recruited from biopharmaceutical companies of all sizes and have decision-making authority at their companies when working with CROs. Individuals completing the survey evaluated companies with whom they had outsourced a project in the past 18 months to ensure the data determining the award winners reflect first-hand experience working with the CROs being evaluated.

About Allucent
Allucent is on a mission to help bring new therapies to light by solving the distinct challenges of its biopharma and government clients. Allucent is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across various therapeutic areas. With more than 30 years of experience in over 60 countries, Allucent's individualized partnership approach provides experience-driven insights and expertise to assist its clients in successfully navigating the complexities of delivering novel treatments to patients. Visit Allucent.com for more information.

SOURCE Allucent


These press releases may also interest you

at 06:02
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major...

at 06:00
Amplify10, the trailblazer in SaaS AI-Powered Sales Execution solutions, proudly announces its official launch today, aimed at reshaping the landscape of sales performance for enterprises worldwide. The early-stage company, formerly known as...

at 06:00
Quhuo Limited ("Quhuo" or the "Company") , a leading gig economy platform focusing on local life services in China, today announced that Ms. Chenxi Zhao has resigned from her position as a member of the board of directors (the "Board"), effective on...

at 05:50
NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have officially entered into a dynamic strategic partnership to collaboratively focus on the future of global health and wellness. Synergistically leveraging their collective expertise...

at 05:45
A report from China.org.cn:  China Duty Free Group (CDFG), the world's leading travel retail operator, outlined its strategy for continued growth at the recently concluded TFWA Asia Pacific Exhibition & Conference held in Singapore from May 12 to...

at 05:35
Drug Farm announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1) inhibitor for clinical evaluation in...



News published on and distributed by: